Mark R. Dowling

The Royal Melbourne Hospital — Australia

Medicine · Health Sciences

32h-index3.8kcitations125works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(18), Receptor Mechanisms and Signaling(14), T-cell and B-cell Immunology(13), Immune Cell Function and Interaction(10), Immunotherapy and Immune Responses(9)

Publications125 total

Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma
Blood·2026
Predicting infection risk following CAR-T using the bedside CAR-HEMATOTOX score: performance in an Australian cohort
Blood Immunology & Cellular Therapy·2025Open Access
Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas
Leukemia & lymphoma/Leukemia and lymphoma·2025
Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.
Blood·2025Open Access
Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement
Blood·2025Open Access
Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience
Blood·2025
A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium
Blood·2025
Long-lived IgE plasma cells persist in secondary lymphoid tissues using a navitoclax-sensitive survival program
Immunity·2025· 5 citedOpen Access
ctDNA MRD after CAR-T
Blood Advances·2025Open Access
DRiving STandard-of-care CAR T cells in real-world Germany
Blood·2025Open Access
In Situ Visualisation of BCMA Bispecific Antibody and the Myeloma Immune Microenvironment
Clinical Lymphoma Myeloma & Leukemia·2025
Cognitive impairment in hematology patients planned for chimeric antigen receptor T-cell therapy
Expert Review of Hematology·2025· 1 cited
Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics
Blood·2025· 5 citedOpen Access
Prognostic Implication of Karyotypic Evaluation in Patients With Richter Transformation in the Modern Era
American Journal of Hematology·2025· 1 citedOpen Access
Brief assessment of cognition in immune effector cell-associated neurotoxicity syndrome
2025Open Access
423 | ctDNA‐DIRECTED INTERVENTION WITH EPCORITAMAB ALONE OR IN COMBINATION WITH LENALIDOMIDE‐RITUXIMAB IS FEASIBLE IN THE EARLY POST‐CAR‐T POPULATION AT HIGH RISK OF RELAPSE
Hematological Oncology·2025Open Access
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL
Blood Cancer Journal·2025· 11 citedOpen Access
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years
Nature Communications·2024· 15 citedOpen Access
Direct Visualisation of BCMA Bispecific Antibody and the Myeloma Immune Microenvironment
Blood·2024
Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry
Blood·2024
page 1 of 7Next →

Frequent Co-authors

Philip D. Hodgkin(15), Steven J. Charlton(8), Cameron Wellard(5), Emma C. Josefsson(5), Benjamin T. Kile(5), Michael A. Nielsen(4), Andrew C. Doherty(4), Andrey Kan(4), John Markham(4), Jie Zhou(4), Edwin D. Hawkins(4), David A. Sykes(4), Julia M. Marchingo(3), Ken R. Duffy(3), Susanne Heinzel(3), Adam S. Kittai(3), David A. Bond(3), Ying Huang(3), Seema A. Bhat(3), Matthew S. Davids(3)